[go: up one dir, main page]

WO1996009059A1 - Procede et composition ameliores destines au traitement des ulceres - Google Patents

Procede et composition ameliores destines au traitement des ulceres Download PDF

Info

Publication number
WO1996009059A1
WO1996009059A1 PCT/AU1995/000625 AU9500625W WO9609059A1 WO 1996009059 A1 WO1996009059 A1 WO 1996009059A1 AU 9500625 W AU9500625 W AU 9500625W WO 9609059 A1 WO9609059 A1 WO 9609059A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
milk
banana
eggs
naturally occurring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AU1995/000625
Other languages
English (en)
Inventor
Brian A. Hills
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of New England
Original Assignee
University of New England
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of New England filed Critical University of New England
Priority to AU35976/95A priority Critical patent/AU3597695A/en
Publication of WO1996009059A1 publication Critical patent/WO1996009059A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Definitions

  • the present invention relates to a method and composition for the prevention, cure and/or soothing of gastro-intestinal ulcers and non-ulcer dyspepsia in mammals in need of such treatment. More particularly the invention relates to a method and composition that can utilise only naturally occurring food grade ingredients.
  • ulcers can form in several parts of the GI tract, e.g. duodenal ulcers, those causing the greatest problem clinically are those forming in the highly acidic conditions of the stomach where the secretion of hydrochloric acid from glands in the stomach wall can lower the pH to about 2.
  • stomach ulcers are caused by the back- diffusion of hydrogen ions, i.e. acid, into the stomach lining.
  • the hydrogen-ion-pump inhibitors and H2 blockers are particularly effective in treating stomach ulcers acutely, but the relapse rate can be as high as 100% over two years (Brit. Med. J., 284: 621, 1982).
  • the patient can be maintained ulcer-free by continually dispensing the acid- suppressing drugs but that raises a new set of problems. Firstly there is the very high cost of continued medication. Secondly there are the side-effects which include excessive gain of weight and gynaecomastia (very unacceptable to males) while there are reports of carcenoid formation in animals subjected to prolonged elevation of pH. Intuitively, it is undesirable to suppress the normal secretion of acid needed to kill bacteria and other unwanted pathogens present in the flora and fauna normally ingested.
  • the major clinical need is for natural foods or a mixture thereof which can be used to maintain the serious ulcer patient who has been successfully treated in the acute phases with H2 antagonists or hydrogen-ion-pump inhibitors.
  • H2 antagonists or hydrogen-ion-pump inhibitors In the general population there is also a real need for a simple remedy to avoid the mild ulceration which can form during stressful periods when our stomachs secrete more acid than usual.
  • the present invention has previously found that gastro-intestinal ulcers may be prevented, cured and/or soothed by the internal administration to a patient of an effective amount of a composition containing a dispersion of ripe banana in milk (see Australian patent specification B29902/89). This previous invention was predicated upon the discovery of lamellar bodies of phospholipid in bananas.
  • the present invention relates to a new composition and method that builds on and extends the previously described invention. Disclosure of the Invention
  • the present invention consists, in a first aspect, in a method for the prevention, curing and/or soothing of gastro-intestinal ulcers or other gastro-intestinal erosion in mammals in need of such treatment, comprising administering orally to such a mammal an effective amount of a composition containing an effective proportion of a naturally occurring phospholipid present in the form of the lamellar bodies and an effective proportion of a naturally occurring hydrophobic protein, the composition being dispersed in a naturally occurring and nutritionally acceptable carrier.
  • the present invention consists in a composition for the prevention, curing and/or soothing of gastro-intestinal ulcers in mammals comprising a composition containing an effective proportion of a naturally occurring phospholipid present in the form of lamellar bodies and an effective proportion of a naturally occurring hydrophobic protein.
  • the present methods are of particular utility in the treatment of gastro-intestinal ulcers and other gastro- intestinal erosion such as gastro-oesophageal reflux (heartburn) and non-ulcer dyspepsia in man, however, it could be used to treat other mammalian animals.
  • the method and composition may be used to ensure the maintenance of a satisfactory protective phospholipid layer in the gastro-intestinal tract and thereby prevent gastro-intestinal ulcers forming.
  • the composition according to this invention and utilised in the method includes a naturally occurring phospholipid present in the form of lamellar bodies.
  • Lamellar bodies are biological stores of highly surface active phospholipid found in animal and plant cells and are described in more detail in B.A. Hills "The Biology of Surfactant” Cambridge University Press 1988 pp 48-51.
  • the most suitable source of lamellar bodies is fruit or vegetables containing such bodies.
  • Most preferably the lamellar bodies are obtained from ripe bananas and are included in the composition by the inclusion of the flesh of the ripe banana fruit in the composition.
  • the banana fruit will have a ripeness of at least stage 7, more preferably stage 8, of the banana growers ripeness scale which ranges from 1 for green to 8 for brown fully mature bananas (see Von Loesecke H.W., "Economic Crops” in Kertesz Z.I, Ed. “Bananas” 2nd Edition, New York, Interscience 1950:108-109).
  • An alternative index of ripeness is the sugar content and on this basis a sugar content of at least 17% by weight, and preferably 20% by weight, is preferred.
  • banana or other fruit or vegetables are used as the source of the phospholipid it is desirable that the fruit or vegetables are dried or frozen rapidly after being peeled or otherwise prepared.
  • the fruit are preferably steamed, rapidly heated or dipped in dilute hypochlorite solution to prevent enzymes turning it brown. This drying or freezing may take place either before or after mixing of the phospholipid components with the other components of the composition.
  • the phospholipid will be naturally occurring and will therefore vary to some extent in composition, however, the phospholipids will typically be straight chained and largely saturated.
  • the predominant and most surface active component will normally be L- ⁇ - dipalmitoyl phosphatidyl choline (DPPC) .
  • DPPC dipalmitoyl phosphatidyl choline
  • phosphatidylethanolamine, phosphatidylserine and phosphatidylinositol will also be present.
  • the composition also contains a naturally occurring source of a hydrophobic protein.
  • the hydrophobic proteins are also called proteolipids in the literature. They are proteins typically extractable from their source with a strongly non-polar solvent such as chloroform or ether.
  • the hydrophobic proteins are associated inter alia with the myelination of axons (nerve fibres) as well as the expansion of the lung at birth. In the latter situations the hydrophobic proteins play a major role in the location of phospholipids at the air-aqueous interface of the neonatal lung upon switching to ventilation by air.
  • hydrophobic proteins may be useful in assisting in the adsorption of phospholipids at a solid surface. He further postulated that such hydrophobic proteins may be present in birds eggs as the developing embryo in the egg must have a rapidly developing nervous system with myelination proceeding very rapidly. He found by experiment that such eggs did indeed contain such hydrophobic protein and that hydrophobic protein does facilitate the adsorption of phospholipids onto solid surfaces. It is therefore a particularly preferred aspect of the invention that the hydrophobic protein component of the composition comprises or is derived from the eggs of birds.
  • the eggs may be whole eggs or egg yolks and may be added to the composition in a wet or dried form.
  • the eggs may be fractionated to increase the proportion of hydrophobic protein in the egg derived material added to the composition.
  • the most readily obtained and economically most advantageous eggs are those derived from chickens, however, eggs from any other avian species could be used with substantially equal effect.
  • Other sources of hydrophobic protein may also be used such as the eggs of non-avian species or the lungs and other suitable tissue of young mammalian animals or the embryos thereof.
  • the components of the composition are preferably dispersed in a suitable carrier for oral administration to the consumer.
  • This carrier may be an aqueous solution of any suitable type but preferably comprises milk, cream or another dairy based liquid.
  • the milk or other dairy based liquid is preferably mixed with the other ingredients in a fresh state and is then rapidly frozen or dried to yield a saleable product.
  • powdered milk produce may be mixed with the other components in a dried state. It is preferred that the banana and milk are mixed prior to drying with the egg being added either fresh before drying or as a dried powder after drying.
  • the preferred milk based liquid is a fat and cholesterol reduced and calcium enriched milk product sold in New South Wales, Australia under the registered trade mark "Shape".
  • the milk and banana are most preferably mixed in a weight/volume ratio of 1:1 i.e. 1 gm of banana is mixed with 1 ml of milk and then dried however this ratio may be varied widely, preferably within the range 8:1 to 1:8. Obviously if other sources of phospholipid are used and other carriers used the ratio could change dramatically, however, the ratios described above may be used as a guide for further routine experimentation of suitable ratios.
  • the egg content may vary widely within the preferred range of 20:1 to 1:20 but, more preferably one part by weight of dried egg yolk powder is added to nine parts by weight of dried banana milk powder. If other sources of hydrophobic proteins and phospholipid are used similar effective ratios would form a starting point for the routine determination of the most effective dose and ratio.
  • polyvalent metal cations such as zinc or calcium may be added to the composition as such polyvalent cations are believed to stabilise the protective phospholipid layer in the gastro-intestinal tract.
  • freeze drying is an appropriate method for treating the banana/milk or egg/banana/milk mixture it is preferably spray dried.
  • the mixture is preferably rapidly heated at the inlet valve of the spray drier. This temperature may not be optimal but it does afford a degree of pasteurisation which is desirable.
  • the heated pure ⁇ is preferably passed through the inlet nozzle directly onto a rapidly spinning disc. This disc disperses the jets of puree into a fine mist in which droplets lose water as they are held in the upward current of air flowing through the dryer.
  • the dried droplets collect at the base of the dryer as a powder.
  • the animal model used was the standard non-pylorus- ligated rat. Wistar rats were starved for 18h. before experimentation during which coprophagy was prevented by keeping each animal in a tube just too small for it to turn around. There was no ligation of the pylorus in these trials so as to avoid variability in acid secretion induced by surgical intervention.
  • the rats were lightly anaesthetised in an atmosphere of 50:50 02:C02 when the test product was administered as a suspension in water via a stomach tube. Control rats were administered 1ml. of water. The rats were given a dose of 5% thiopentone sodium as a maintenance anaesthetic. After lh. the acid insult was administered by stomach tube, consisting of lml.
  • the dose was 250mg in lml water for a 270gm rat.
  • the rats were killed 2h. later by a lethal dose of sodium pentobarbitone after which the stomachs were excised and laid flat on a light box with the mucosal side uppermost.
  • the damage was then assessed by strongly illuminating the mucosa and projecting an image into a video-camera from which the ulcerated area could be clearly defined by colour enhancement.
  • the ulcerated area was then determined as a percentage of total mucosal area by computerised topography. This process, together with identical colour enhancement of controls, was felt to minimise, if not eliminate, any operator bias.
  • Ripe bananas were rapidly dispersed in a dairy product being a calcium enriched fat reduced milk sold under the registered trade mark "SHAPE" when the temperature is immediately raised and the puree injected into a spray-drier to produce a banana/dairy (BD) product.
  • BD banana/dairy
  • whole eggs (minus shell) or egg yolks are also incorporated into the ⁇ ure6 to be sprayed to produce an egg- banana-dairy (EBD) product.
  • the spray-dried powder is continuously removed from the drier. If egg was not added to the initial puree, then egg-yolk powder is mixed with the BD product by tumbling the two powders together to produce a mixed powdered egg/banana/dairy product (PEBD) .
  • PEBD mixed powdered egg/banana/dairy product
  • PE is more effective than raw egg yolk (E) in enhancing the efficacy of fresh banana dispersed in dairy product, further reducing mean ulcerated area by XA£ £_2
  • PE spray-dried egg-yolk powder
  • BD spray-dried banana/dairy product
  • EBD co-spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé et une composition permettant de prévenir, de guérir et/ou de calmer les effets des ulcères et autres phénomènes d'érosion gastro-intestinale chez les mammifères nécessitant un tel traitement, y compris l'homme. On administre au sujet une dose efficace d'une composition contenant un phospholipide naturel sous forme de corps lamellaires, et une protéine hydrophobe naturelle dans un excipient naturel, acceptable sur le plan nutritionnel. La composition contient de préférence un mélange, déshydraté et sous forme de poudre, de bananes, d'oeufs et de lait, qui peut être dissous dans du lait ou de l'eau.
PCT/AU1995/000625 1994-09-23 1995-09-22 Procede et composition ameliores destines au traitement des ulceres Ceased WO1996009059A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU35976/95A AU3597695A (en) 1994-09-23 1995-09-22 Improved method and composition for the treatment of ulcers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPM8367A AUPM836794A0 (en) 1994-09-23 1994-09-23 Improved method and composition for the treatment of ulcers
AUPM8367 1994-09-23

Publications (1)

Publication Number Publication Date
WO1996009059A1 true WO1996009059A1 (fr) 1996-03-28

Family

ID=3782886

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1995/000625 Ceased WO1996009059A1 (fr) 1994-09-23 1995-09-22 Procede et composition ameliores destines au traitement des ulceres

Country Status (2)

Country Link
AU (1) AUPM836794A0 (fr)
WO (1) WO1996009059A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030226A1 (fr) * 2003-09-25 2005-04-07 Lamellar Therapeutics Limited Compositions et procedes pour utiliser des corps lamellaires a des fins therapeutiques
AU2004210207B2 (en) * 2003-02-10 2009-12-10 Provexis (Ibd) Limited Treatment of inflammatory bowel disease
US9173901B2 (en) 2003-09-25 2015-11-03 Lamellar Therapeutics Limited Compositions and methods of using lamellar bodies for modifying linear biological macromolecules

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2990289A (en) * 1988-02-11 1989-08-17 University Of New England, The A method for the prevention, curing and/or soothing of gastro-intestinal ulcers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2990289A (en) * 1988-02-11 1989-08-17 University Of New England, The A method for the prevention, curing and/or soothing of gastro-intestinal ulcers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADELLE DAVIS, "Let's Get Well", Published 1983, by UNWIN PAPERBACKS (LONDON), Chapter 8, pages 67-68, Chapter 33, 301-303. *
CHEMICAL ABSTRACTS, Volume 104, Number 9, issued March 3, 1986, (Columbus, Ohio, USA), YASUI, WATARU et al., "Calcium-Activated, Phospholipid-Dependent Protein Kinase in Human Gastric Mucosa and Carcinoma", page 510, Abstract No. 66831u; & JPN. J. CANCER RES., 1985, 76(12), 1168-73. *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004210207B2 (en) * 2003-02-10 2009-12-10 Provexis (Ibd) Limited Treatment of inflammatory bowel disease
WO2005030226A1 (fr) * 2003-09-25 2005-04-07 Lamellar Therapeutics Limited Compositions et procedes pour utiliser des corps lamellaires a des fins therapeutiques
AU2004275550B2 (en) * 2003-09-25 2011-08-18 Lamellar Biomedical Limited Compositions and methods of using lamellar bodies for therapeutic purposes
US9173901B2 (en) 2003-09-25 2015-11-03 Lamellar Therapeutics Limited Compositions and methods of using lamellar bodies for modifying linear biological macromolecules
US9750766B2 (en) 2003-09-25 2017-09-05 Lamellar Biomedical Limited Compositions and methods of using lamellar bodies for modifying linear biological macromolecules

Also Published As

Publication number Publication date
AUPM836794A0 (en) 1994-10-20

Similar Documents

Publication Publication Date Title
JP6924308B2 (ja) 押出ペットフード製品
KR20180080256A (ko) 조합된 프리- 및 프로-바이오틱 조성물
JPWO2009011288A1 (ja) カルシウムイオン徐放剤
KR20220083535A (ko) 반려동물 심장 기능 개선용 조성물 및 이를 포함하는 기능성 식품
CN109498542A (zh) 一种用于抗幽门螺杆菌的生物牙膏
KR20240004268A (ko) 안정화된 초유 조성물
EP1139784B1 (fr) Proteines antisecretrices induites par l'alimentation, notamment le jaune d'oeuf
US6428817B1 (en) Companion animal therapeutic treat
CA2992057C (fr) Procede de production de jaune d'oeuf ayant une teneur elevee en af-16
WO1996009059A1 (fr) Procede et composition ameliores destines au traitement des ulceres
JP2018531214A6 (ja) 高含量のａｆ−１６を有する卵黄の産生方法
CA2336602C (fr) Friandise therapeutique pour animaux de compagnie
ITMI20010545A1 (it) Alimento di attivazione intestinale utilizzante polvere di natto
JPH0438381B2 (fr)
AU2005289330A1 (en) Rehydration compositions comprising epidermal growth factor
CN1066917C (zh) 用蛋壳粉强化的奶制品
JP2009120519A (ja) 消化管潰瘍の予防又は治療剤
CN106616008A (zh) 一种防治腮腺炎的甲鱼饲料
JPS5936890B2 (ja) 制癌剤
KR102663613B1 (ko) 형개 추출물을 유효성분으로 포함하는 고양이 전염성 복막염 예방 또는 치료용 조성물
KR102467088B1 (ko) 식감을 개선한 진미채 튀김 및 이의 제조 방법
KR100745569B1 (ko) 유기태 아연과 망간이 함유된 오리 사육용 사료 및 그사료를 이용한 오리의 사육방법
KR100655504B1 (ko) 유황 제독방법
KR20240150638A (ko) 반려동물 안구 건조 및 눈물 예방을 위한 조성물
KR20150060465A (ko) 후라이드 치킨 및 이의 제조방법

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase